Director, AbbVie
Regulatory Outlook for Atogepant in Migraine: Lawrence Severt, MD, PhD
The director at AbbVie discussed the timeline for when a regulatory decision may come for migraine treatment atogepant, and whether additional trials are necessary.
Advantages of Atogepant in Ever-Growing CGRP Market: Lawrence Severt, MD, PhD
The director at AbbVie highlighted where atogepant stands among the increasing treatment landscape of anti-calcitonin gene-related peptide options within the migraine treatment landscape.
Atogepant Continues to Shine in Phase 3 ADVANCE Study: Lawrence Severt, MD, PhD
The director at AbbVie discussed a number of abstracts presented at AAN 2021 involving atogepant and its phase 3 ADVANCE study.
